ResApp Health is the world’s first digital diagnostic application of a smartphone for the diagnosis of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies at leading hospitals in Australia and the United States have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infections, asthma/reactive airway disease, pneumonia, bronchiolitis, croup, chronic obstructive pulmonary disease and obstructive sleep apnoea. Regulatory filings submitted in the US and Europe. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world.
Tony Keating – CEO & Managing Director
Tony was formerly the Director of Commercialisation at the University of Queensland.
Brian Leedman – VP Corporate
Brian is a biotechnology entrepreneur having founded a number of ASX healthcare companies and formerly Chairman of Ausbiotech (WA).
What is your rationale for attending 121 Tech Investment?
Looking for investors and commercialisation partners
What recent news would you like to highlight to investors attending?
Regulatory submissions filed in the US and EU with decisions pending.
What are your key goals for the next 3, 6 and 12 months?
Regulatory approvals in key markets
Commercialisation generating substantive revenues
Partnerships/ licensing agreements
What do you see as the key risks and challenges facing your company at the moment and how are you overcoming these?
What do you think makes your company such a compelling investment?
Unique technology with huge commercial potential